Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 8/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976585 | 1.00 | NPC1 (0.45) | NPC1RAB9ATDP1GPR183MAPT | |
| SCHEMBL4974630 | 0.91 | MAPT (0.52) | NPC1RAB9AGPR183MAPTSMN1; SMN2 | |
| SCHEMBL4974626 | 0.91 | MAPT (0.52) | NPC1RAB9AGPR183MAPTSMN1; SMN2 | |
| SCHEMBL4976605 | 0.89 | ALDH1A1 (0.44) | MAPTGAAHSP90AB1 | |
| SCHEMBL4976589 | 0.89 | ALDH1A1 (0.44) | MAPTGAAHSP90AB1 | |
| SCHEMBL14346864 | 0.88 | HSP90AB1 (0.42) | NPC1RAB9AGPR183MAPTGAA | |
| SCHEMBL4980006 | 0.87 | MAPT (0.46) | NPC1RAB9AGPR183MAPTSMN1; SMN2 | |
| SCHEMBL4976529 | 0.87 | HSP90AB1 (0.47) | NPC1RAB9AGPR183MAPTGAA | |
| SCHEMBL4976525 | 0.87 | HSP90AB1 (0.47) | NPC1RAB9AGPR183MAPTGAA | |
| SCHEMBL4980014 | 0.87 | MAPT (0.46) | NPC1RAB9AGPR183MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | NPC1 4289/4885RAB9A 2216/4885TDP1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.